{"id":"fenofibrate-omega","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fenofibrate is a fibrate that works primarily through PPARα activation, which increases lipolysis and reduces VLDL production, thereby lowering triglycerides and raising HDL cholesterol. The addition of omega-3 fatty acids (likely eicosapentaenoic acid and/or docosahexaenoic acid) provides complementary triglyceride reduction and anti-inflammatory benefits. This combination targets dyslipidemia and cardiovascular risk reduction through complementary mechanisms.","oneSentence":"Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and improve lipid profiles, while omega-3 fatty acids provide additional triglyceride-lowering and anti-inflammatory effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:20.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia"},{"name":"Dyslipidemia with elevated triglycerides"}]},"trialDetails":[{"nctId":"NCT04140201","phase":"PHASE4","title":"Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients","status":"UNKNOWN","sponsor":"Alaa Hassan ElBaz","startDate":"2020-02","conditions":"Diabetic Retinopathy","enrollment":80},{"nctId":"NCT01666041","phase":"PHASE4","title":"Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2012-01","conditions":"Hypertriglyceridemia","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":117,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"fenofibrate/omega","genericName":"fenofibrate/omega","companyName":"Gachon University Gil Medical Center","companyId":"gachon-university-gil-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and improve lipid profiles, while omega-3 fatty acids provide additional triglyceride-lowering and anti-inflammatory effects. Used for Hypertriglyceridemia, Dyslipidemia with elevated triglycerides.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}